New Florida facility will create hundreds of new jobs and produce 25 critical respiratory medicines and inhalers
WASHINGTON (October 7, 2025) — The Association for Accessible Medicines today commented on the announcement by Lupin Limited to invest $250 million in the U.S. and build a new manufacturing facility in Coral Springs, Florida. This investment in U.S. manufacturing will create over 1,000 construction jobs and over 200 long-term skilled manufacturing jobs by 2030 and strengthen domestic manufacturing and enhance supply chain diversification. The new facility will have the capacity to produce more than 25 critical respiratory medicines and inhalers.
“Lupin’s investment of $250 million to produce more than 25 critical medicines in the United States will not only help patients, especially children with asthma, it will also add resilience to our supply chain and diversify our manufacturing base,” said John Murphy III, President and CEO of the Association for Accessible Medicines.“
AAM members are committed to researching, developing, and manufacturing safe, affordable, and accessible medicines. We will continue to work with regulators, legislators, and the administration on reforms that will boost domestic manufacturing and break down the many barriers facing affordable medicines.” Lupin joins fellow AAM members in their commitment to domestic manufacturing and U.S. investment. In June, Hikma announced the groundbreaking of a new facility in Ohio and the expansion of facilities in Ohio and New Jersey. In July, Amphastar announced an expansion of its California facilities that will quadruple their production within five years.
###
Lupin press release: https://www.lupin.com/lupin-announces-plans-to-build-a-new-state-of-the-art-manufacturing-facility-in-coral-springs-florida
Amphastar press release: https://ir.amphastar.com/news/amphastar-pharmaceuticals-aims-to-quadruple-domestic-manufacturing-capacity-at-rancho-cucamonga-headquarters/85683e00-ad06-49f7-aab5-b4891cecb6b1
Hikma press release: https://www.prnewswire.com/news-releases/hikma-pharmaceuticals-usa-announces-1-billion-of-new-us-investment-to-further-expand-its-domestic-manufacturing-and-development-of-essential-generic-medicines-302493824.html
2025 U.S. Generic & Biosimilar Medicines Savings Report: https://accessiblemeds.org/resources/reports/2025-savings-report
For media inquiries, contact media@accessiblemeds.org.
About AAM
The Association for Accessible Medicines, your generics and biosimilars industry, is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. AAM represents the manufacturers of finished generic pharmaceuticals and biosimilars, manufacturers of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 12 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines, works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is the leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, government affairs, legal affairs, and regulatory policy. More information is available biosimilarscouncil.org.
